You are here: Industry Insights > Market News > Shanghai Fosun Forms $50M U.S. JV - With Itself

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

Shanghai Fosun Forms $50M U.S. JV - With Itself

biospaceJanuary 12, 2018

Tag: joint venture , Fosun

Favorites

Shanghai Fosun Pharma announced a $50 million US joint venture, a JV that includes two Fosun entities. Fosun Pharma USA will pay $25.5 million to own a 51% interest in the new JV, which was not named, and Fosun International, the conglomerate that is the parent of Fosun Pharma and its largest shareholder, will contribute the remainder, $24.5 million. Not much is known about the rationale behind the JV, except that it will be located in the US and focused on innovation in R&D, manufacturing, medical devices and medical diagnosis, which is not a very specific explanation.

Previous:FDA Panel Rejects Lipocine's Testosterone Pill

Next:The 7 Best Life Science Companies to Work for in 2018

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Shanghai Fosun Forms $50M U.S. JV - With Itself | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

Shanghai Fosun Forms $50M U.S. JV - With Itself

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

You may like
More>>

Shanghai Fosun Forms $50M U.S. JV - With Itself

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

You may likeMore>>

You may like
More>>